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The promyelocytic leukemia zinc finger (PLZF) protein, also known as Zbtb16 or Zfp145,
was first identified in a patient with acute promyelocytic leukemia, where a reciprocal chro-
mosomal translocation t (11;17)(q23;q21) resulted in a fusion with the RARA gene encoding
retinoic acid receptor alpha.The wild-type Zbtb16 gene encodes a transcription factor that
belongs to the POK (POZ and Krüppel) family of transcriptional repressors. In addition to
nine Krüppel-type sequence-specific zinc fingers, which make it a member of the Krüppel-
like zinc finger protein family, the PLZF protein contains an N-terminal BTB/POZ domain and
RD2 domain. PLZF has been shown to be involved in major developmental and biological
processes, such as spermatogenesis, hind limb formation, hematopoiesis, and immune
regulation. PLZF is localized mainly in the nucleus where it exerts its transcriptional repres-
sion function, and many post-translational modifications affect this ability and also have an
impact on its cytoplasmic/nuclear dissociation. PLZF achieves its transcriptional regulation
by binding to many secondary molecules to form large multi-protein complexes that bind to
the regulatory elements in the promoter region of the target genes. These complexes are
also capable of physically interacting with its target proteins. Recently, PLZF has become
implicated in carcinogenesis as a tumor suppressor gene, since it regulates the cell cycle
and apoptosis in many cell types.This review will examine the major advances in our knowl-
edge of PLZF biological activities that augment its value as a therapeutic target, particularly
in cancer and immunological diseases.
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INTRODUCTION
The family of zinc finger proteins is composed of regulatory pro-
teins that participate in many molecular and cellular pathways
and is considered to be one of the most profuse regulatory protein
families in eukaryotic cells, with more than 200 members. Dif-
ferent members of the zinc finger protein family contain multiple
cysteine (Cys) and/or histidine (His) residues that require one or
more zinc ions to stabilize their structures. The majority of the
zinc finger proteins play important roles in DNA binding, RNA
binding, RNA packaging, and protein–protein interactions. The
family is divided into three sub-groups according to structure and
the number of zinc fingers (Laity et al., 2001).
The zinc finger and BTB domain containing 16 (Zbtb16) gene
was first described in humans in 1993, where its encoded protein
was found to be fused in-frame with the retinoic acid receptor
alpha (RARα) in a patient diagnosed with a rare form of acute
promyelocytic leukemia (APL) with a reciprocal chromosomal
translocation t (11;17). The protein was named the promyelocytic
leukemia zinc finger (PLZF), because it was the first zinc finger
family member exhibiting a pronounced effect on the pathology
of promyelocytic leukemia (Chen et al., 1993).
In humans, the gene is localized to chromosome 11q23 among
a cluster of genes, all related to the zinc finger family. The gene
has three splice variants (transcripts), all encoding functional
proteins, and composed of seven exons with shared homology
between exons 3 and 6. The first transcript (ENST00000335953)
is 2,477 bp in length and encodes a 673 aa protein. The second
transcript (ENST00000392996) is 2,249 bp in length and encodes
a 673 aa protein. The third transcript (ENST00000310883) is
1,728 bp in length and encodes a 550 aa protein. In mouse, the
gene is located in chromosome 9, and is composed of seven exons.
However, unlike its human analog, it only has one transcript
(ENSMUST00000093852) that is 5,100 bp in length and encodes
a 673 aa protein, which is similar in length to the human analog
transcripts 2 and 3.
The N-terminus of the protein (as seen in Figure 1) con-
tains a Drosophila-like bric à brac, tramtrack, and broad-complex
domain called BTB (Zollman et al., 1994). This domain is also
known as the poxvirus and zinc finger (POZ) domain and is highly
conserved in mammals and plays a major role in DNA looping
as well as protein dimerization and interaction to form multi-
protein complexes (Bardwell and Treisman, 1994; Yoshida et al.,
1999). The middle region of the protein has an RD2 domain that
is less characterized and understood than the BTB/POZ domain,
although mutations in this domain modulate the transcriptional
activity of PLZF (Kang et al., 2003). The C-terminus of the pro-
tein contains nine Krüppel-like C2H2 zinc fingers that facilitate
sequence-specific DNA binding to its target genes allowing PLZF
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FIGURE 1 | Structure of PLZF. (A) The 3D crystal structure of PLZF resolved
using X-ray diffraction [PDB ID: 1CS3, Resolution (Å): 2.00; Li et al., 1999].
PLZF contains two β strands in its N-terminal sequence along with a BTB
domain, and one α helix in the C-terminal with nine zinc finger motifs. (B) The
full-length primary transcript of PLZF (Gene ID: 7704, Transcript ID:
ENST00000335953) with its three functional domains: the BTB/POZ domain,
the RD2 domain, and the zinc finger domain. Some of the important biological
functions of each domain are also outlined. PLZF has three splice variants
(transcripts), all encoding functional proteins, and composed of seven exons
with shared homology between exons 3 and 6.
to act as a transcriptional repressor (Li et al., 1997). The promoter
region of human PLZF starts about 6 kb upstream of the ATG
starting codon. The first TATA box in the human genomic DNA
sequence for the PLZF gene appears at position 6,108 in the 5′
UTR. A very GC rich region is also found about 2 kb upstream of
the ATG codon.
The involvement of PLZF in blocking the differentiation of
promyelocytes and causing leukemia led the way for researchers
to investigate its role in many biological activities regulating cellu-
lar proliferation and differentiation. Earlier reports confined the
expression of PLZF to stem cells and early progenitor cells (Sha-
knovich et al., 1998), but it is now known that PLZF is expressed
in many of the CNS cells, hematopoietic cells in the bone mar-
row, glandular cells in the gallbladder, islets of Langerhans in the
pancreas, respiratory epithelial cells, myocytes in the heart and
skeletal muscles, endometrial stroma in the uterus, glomeruli and
renal tubules, glandular cells of many parts of the gastrointestinal
tract, prostate, and endocrine glands (Uhlén et al., 2005).
PLZF ANIMAL MODELS
A model of PLZF (ZBTB16) gene knockout was developed in 2000
by researchers at Memorial Sloan-Kettering Cancer Center (Cor-
nell University). They replaced the second exon of full-length PLZF
with the neomycin resistance gene. PLZF−/−mice displayed major
musculoskeletal-limb defects with homeotic transformations of
vertebral segments, deformed cartilage and skeleton patterning,
and alterations in digit formation that is caused by an inhibition
of apoptosis in hindlimb early progenitor cells in the autopod
region possibly due to Hox gene regulation (Barna et al., 2000).
Moreover, PLZF was shown to be specifically essential for spa-
tial colinear expression of HoxD genes that are expressed in the
hindbrain. This was achieved by the active recruitment of his-
tone deacetylases (HDACs), possibly through the PLZF-mediated
interaction with polycomb family members such as Bmi-1, to the
promoters of the Hox gene clusters affecting only the development
of the posterior regions of the limb bud (Barna et al., 2002).
Another role for PLZF also emerged after assessing Gli3 and
PLZF double knockout mouse embryos, where their cooperation
was shown to be required for proximal cartilage condensations
in the hindlimb by orchestrating the necessary dissemination of
chondrocyte progenitor cells in the proximal limb bud, inde-
pendent of proximal-distal patterning (Barna et al., 2005). PLZF
expression is also important in osteoblastic differentiation, since it
is an upstream regulator of core-binding factor 1 (CBFA1/Runx2).
CBFA1 affects many important factors during the pluripotent dif-
ferentiation of human mesenchymal stem cells (hMSCs) into the
osteogenic lineage such as collagen 1A1 (COL1A1), alkaline phos-
phatase (ALP), and osteocalcin (OCN). Loss of PLZF expression
during the early stages of pluripotent differentiation of hMSCs
leads to the disruption of spinal ossification (Ikeda et al., 2005).
PLZF−/− male mice show partial sterility, which is caused by
markedly impaired spermatogenesis. Spermatozoal maturation in
the seminiferous tubules was found to be distinctly decreased
as a result of increased apoptosis in spermatogonial cells (Kelly
and Daniel, 2006). This confirmed previous studies suggesting a
dynamic role for PLZF in maintaining the undifferentiated state
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of spermatogonial cells, where the loss of this expression disrupts
the balance between stem cell self-renewal and differentiation
(Buaas et al., 2004). It was later confirmed that PLZF binds to the
c-Kit promoter in a spatial and temporal-dependent fashion, to
inhibit the maintenance and proliferation of postnatal germ cells
(Filipponi et al., 2007).
PLZF−/− mice were also found to be more prone to viral
infections. Exposing neonatal wild-type and PLZF−/− mice to
the Semliki Forest virus (SFV) was lethal as measured by survival
curves. However, pretreating the mice with interferon (IFN) for
6 h prior to infection protected the wild-type neonatal mice from
infection, with survival times exceeding 3 weeks. On the other
hand, mice lacking PLZF expression died after 6 days of infection,
with viral loads in their vital organs about a thousand times higher
than wild-type mice after only 48 h post-infection. This occurred
despite the fact that both genotypes expressed comparable levels of
IFNs after infection, showing that activation of certain anti-viral
genes was impaired in the absence of PLZF. Similarly, introducing
the encephalomyocarditis virus (EMCV) via intraperitoneal injec-
tions to wild-type and PLZF−/− mice yielded equivalent results
when comparing survival curves between the two genotypes (Xu
et al., 2009). This demonstrates the requirement for PLZF in the
IFN-mediated anti-viral innate immune response in vivo. The
impairment of the IFN response was due to the failure to induce
a subset of IFN-stimulated genes (ISGs), accounting for the fatal
phenotype in PLZF−/−mice. Moreover, IFN-induced activation of
natural killer (NK) cells was also impaired in PLZF−/−mice, which
was attributed to the marked decrease in CXCL10 expression in
NK-cell-rich organs in these animals (Xu et al., 2009).
POST-TRANSCRIPTIONAL REGULATION
One of the ways the cell uses to control the expression profile
of different proteins is to regulate steps in the processing of the
primary RNA transcript to mature mRNA. Control of RNA pro-
cessing before protein synthesis is a very effective method for gene
regulation and silencing, and allows for rapid and effective silenc-
ing of gene expression. Eukaryotic cells employ many processes
to achieve this type of regulation, such as m7G 5′ capping, 3′ tail
polyadenylation, and intron splicing. MicroRNAs are also key reg-
ulators of post-transcriptional events via binding complementary
sequences in the 5′ or 3′ UTR of their target mRNA transcripts
to block translation and/or cause Ago2-dependent degradation
(Hansen et al., 2011).
Promyelocytic leukemia zinc finger has been shown to regulate
the expression of miR-146a in vitro in a PLZF-positive HEL cell
line. PLZF binds directly to the promoter of miR-146a and inhibits
its transcription, leading to an up-regulation of CXCR4 protein.
CXCR4 is a chemokine that is crucially involved in the mobiliza-
tion of normal hematopoietic as well as leukemic cells. It is also
required for the proliferation, differentiation, and maturation of
CD34+ megakaryocytic-progenitor cells, as demonstrated by an
increase in the levels of the megakaryocytic markers CD9, CD41,
and CD61(Labbaye et al., 2008).
Promyelocytic leukemia zinc finger has also been shown to
target the promoter region of miR-221/222 to inhibit their tran-
scription in different PLZF-transduced melanoma cell lines.
PLZF-positive melanocytes show a less malignant phenotype.
Conversely, increased levels of miR-221/222, in PLZF-negative
cells, correlate with increased tumorigenicity of these cells, as
reflected by a decrease in G1 phase and a corresponding increase
in S and G2-M phases, as well as an enhanced proliferation rate,
invasiveness, motility, and anchorage-independent growth. The
inhibition of these miRNAs causes an up-regulation of c-Kit,
which is required for melanogenesis (Felicetti et al., 2008).
POST-TRANSLATIONAL MODIFICATION
ACETYLATION
Acetylation is the reversible addition of an acetyl group to lysine
residues in proteins, which has a major effect on their functions
and interactions. Lysine residues in PLZF zinc finger 9 were shown
to be acetylated by p300 both in vitro and in vivo. This acetylation
is detrimental for PLZF binding to the specific DNA sequence
5′-TACTGTAC-3′, which is found in the promoters of its target
genes. Mutating these lysine residues prevented PLZF from bind-
ing to this sequence and it subsequently lost its transcriptional
repression, as evidenced by the failure to inhibit the growth of
epithelial-like osteosarcoma cells in vitro. Since this process only
affected the zinc fingers, which are necessary for DNA binding,
neither PLZF stability nor its binding capacity to other proteins
were affected (Guidez et al., 2005).
PHOSPHORYLATION
Phosphorylation is the reversible addition of a phosphate group
to serine and threonine residues of a protein, which modulates
its function by prompting conformational changes in 3D struc-
ture or activation of its kinase ability. PLZF was shown to be
phosphorylated by cdc2/Cyclin-B in vitro, which affected its DNA-
binding ability to the promoter of many transcription factors such
as c-Jun and GATA1 (Ball et al., 1999). Cyclin-dependent kinase
(CDK)-2 was also reported to phosphorylate PLZF at threonine
residue 282 and serine residue 197 in vitro (Table 1). Unlike cdc2
phosphorylation, which directly regulates PLZF transcriptional
function, CDK2-mediated phosphorylation of PLZF did not affect
its nuclear localization but rather induced its ubiquitination and
subsequent degradation, indirectly regulating its function. Muta-
tion of those phosphorylation sites caused PLZF to become even
more transcriptionally repressive compared to the wild-type PLZF
(Costoya et al., 2008).
Interferon was also reported to cause the phosphorylation of
PLZF at serine residue 76 in vitro. This phosphorylation identi-
fied mitogen-activated protein kinase 8 (JNK) or a kinase in the
same pathway to be the responsible enzyme. The study demon-
strated that PLZF transcriptional activity is enhanced and caused
the binding of PLZF to the promoter of many ISGs. Unlike its
previously reported transcriptional repression activity, following
IFN stimulation, PLZF acted as a transcriptional activator, which
was a novel finding for this zinc finger protein family member (Xu
et al., 2009).
SUMOYLATION
Small ubiquitin-like modifier (SUMO) proteins are a family of
small proteins that reversibly attach to their target proteins to reg-
ulate their functions. SUMO-1, a SUMO protein family member,
binds to lysine 242 residue in the RD2 domain of PLZF in vivo. It
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Table 1 | Post-translational modifications of PLZF.
Modification Effector Site Biological effect Reference
Acetylation P300 K647 Inhibits PLZF transcriptional repression through its ninth zinc finger Guidez et al. (2005)
K650 Modulates PLZF ability to bind specific DNA sequences
K653 Suppresses cellular growth
Phosphorylation CDK2 S197 Regulates PLZF stability and its degradation potential Costoya et al. (2008)
T282 Activates cyclin-A2, which drives cell cycle progression
Sumoylation SUMO-1 K242 Regulates PLZF transcriptional repression through its RD2 domain Kang et al. (2003)
Modulates PLZF DNA-binding capacity
Affects many PLZF biological activities
Ubiquitination BTBD6 BTB Marks PLZF for proteasomal degradation and nuclear export Sobieszczuk et al. (2010)
domain Antagonizes PLZF inhibition of neurogenesis
abrogates the DNA-binding ability of PLZF and therefore relieves
its transcriptional repression on cell cycle progression through re-
activation of cyclin-A2 (Kang et al., 2003). Another recent study
has shown that metadherin (MTDH) binds to sumoylation sites in
the RD2 terminal of PLZF while inside nuclear bodies. This inter-
action significantly hindered the ability of PLZF to bind the c-myc
promoter and relieved its transcriptional repression. Moreover,
MTDH binding to PLZF increased its complex formation with
HDAC4 in favor of HDAC1, two well-known HDACs with which
PLZF interacts to achieve its inhibitory effect through chromatin
remodeling (Thirkettle et al., 2009). This could also explain the
potential variability of the PLZF/HDAC interaction, which leads to
opposite transcriptional fates depending on the post-translational
modification of PLZF.
UBIQUITINATION
Ubiquitin is a highly conserved small protein found only in eukary-
otes. Its main function is to bind other proteins that are not
needed in the cell and mark them for proteasomal degradation.
Through this process (ubiquitination or ubiquitylation), ubiqui-
tin modulates many biological processes by targeting different
proteins in various pathways directing them for biological recy-
cling. The BTB/POZ domain of PLZF was shown to bind BTBD6,
a known ubiquitin ligase adaptor protein for the CUL3 ubiqui-
tin E3 ligase complex, leading to its export from the nucleus and
subsequently its degradation. The removal of PLZF from the cell
was shown to be essential for differentiation of neural progenitor
cells during the early stages of neurogenesis, possibly by restor-
ing NEUROG1 expression (Sobieszczuk et al., 2010), emphasizing
its role in regulating stem cell self-renewal. Recently, an antag-
onistic relationship between SUMO-1 and ubiquitin for lysine
residue 242 in the RD2 domain of PLZF was suggested. This was
linked to abnormal physiological conditions of cells in culture,
such as serum deprivation, which increase reactive oxygen species
(ROS) and subsequently modulate PLZF function through either
ubiquitination or sumoylation (Kang et al., 2008).
PLZF AND CELLULAR BIOLOGY
LOCALIZATION IN THE CELL
After the discovery of the PLZF gene in 1993, the protein prod-
uct was subsequently noted to be localized inside the nucleus
within specialized nuclear compartments called nuclear speckles
(Koken et al., 1997). Nuclear speckles or interchromatin granule
clusters are specialized organelles that contain large numbers of
transcription factors and are involved in pre-mRNA processing
and truncation (Spector and Lamond, 2011). Many studies have
shown that PLZF transcriptional repression is carried out while the
protein is localized inside these nuclear compartments, and once
PLZF is shuttled outside of the nuclear speckles, the repression
is lost. For instance, phorbol ester 12-O-tetradecanoylphorbol-
13-acetate (TPA) treatment of human fibrosarcoma HT1080
cells caused the metalloprotease cleavage of membrane-anchored
heparin-binding EGF-like growth factor (proHB-EGF) into its sol-
uble form HB-EGF-C. This soluble form is known to bind the zinc
finger motif of PLZF and mediates its nuclear export into the cyto-
plasm. The decrease in PLZF nuclear level in TPA-treated HT1080
cells led to increased cyclin-A2 levels, a known PLZF-target gene,
which was responsible for cell cycle progression into the S-phase
(Nanba et al., 2003). Conversely, many other substances increase
PLZF expression inside nuclear speckles and therefore increase its
transcriptional activity, such as seen after retinoic acid and IFN
treatment (Koken et al., 1999).
SELF-RENEWAL vs. DIFFERENTIATION
Promyelocytic leukemia zinc finger plays a key role in both the
renewal and maintenance of stem cells and early progenitor cells.
Reid et al. studied early hematopoietic progenitors and showed
that PLZF is expressed in high levels in undifferentiated, multi-
potential hematopoietic progenitor cells. They also demonstrated
how PLZF expression declined when these cells were committed to
a specific hematopoietic lineage and started to differentiate (Reid
et al., 1995). During early erythropoiesis, PLZF regulates both
myeloid and erythroid CD34+ lineages as they proliferate, con-
trolling their commitment to differentiation. PLZF binds to the
promoter of c-Kit and inhibits its expression. c-Kit activation by
its ligand, the stem cell factor (SCF), is known to be crucial for the
maintenance and differentiation of hematopoietic stem cells and
hematopoietic progenitor cells (Muta et al., 1995). The disruption
of c-Kit by PLZF inhibits proliferation and maturation of CD34+
cells. Despite the negative effect of PLZF on the cell cycle of differ-
entiated cells, high levels of PLZF are accompanied by fast growth
in early hematopoietic progenitor cells, showing that not only is
PLZF function dependent on cell type, but it is also required for
maintaining the self-renewal capacity of the progenitor cells (Dai
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et al., 2002). The capacity of male germ line stem cells (spermato-
gonial cells) to maintain their numbers through self-renewal has
also been linked to PLZF function (Buaas et al., 2004). This is
thought to be achieved through the interaction of PLZF with a
polycomb ring finger oncogene known as BMI1, which was iden-
tified to be required for hematopoietic and leukemic self-renewal
ability (Park et al., 2003). A list of proteins that interact with PLZF
is given in Table 2.
Moreover, inactivation of PLZF in mouse models leads to the
exit of spermatogonial cells from a quiescent state of regeneration
and the subsequent entry into meiosis, leading to testicular degen-
eration as a result of increased apoptosis (Costoya et al., 2004).
This dependency of stem cells and early progenitor cells on PLZF
expression, which is required for embryonic tissue development,
does not stop after maturation. PLZF was recently linked to the
maintenance of adult stem cell populations through the modula-
tion of Sal-like protein 4. Sall4 is another zinc finger transcription
factor that is involved in embryonic stem cell pluripotency and
early embryonic development by driving differentiation through
c-Kit activation (Zhang et al., 2006). The POZ/BTB domain of
Table 2 | PLZF interacting partners.
Protein Association Function Reference
AT2 receptor Protein–protein interactions Promotes cardiac hypertrophy, and is vital for programmed cell death
(apoptosis)
Senbonmatsu et al. (2003)
BCL6 Protein–protein interactions Involved in leukemogenesis Wong and Privalsky (1998)
CRMP-1 Complex formation Modulates sialic acid synthesis necessary for cell–cell interactions and is
involved in the organization of the cellular cytoskeleton
Weidemann et al. (2006)
CUX1 Promoter interaction Blocks PLZF transcriptional activity in vivo and in vitro Fréchette et al. (2010)
DRAL/FHL2 Protein–protein interactions Augments PLZF transcriptional repression McLoughlin et al. (2002)
EEF1A1 Protein–protein interactions Inhibits SiHa cervical cancer cell growth by inducing apoptosis and
suppressing human cyclin-A2 promoter activity
Rho et al. (2006)
ETO Complex formation Inhibits PLZF transcriptional repression Melnick et al. (2000)
FAZF Heterodimerization Augment PLZF transcriptional repression and binds to the same target
genes as PLZF
Hoatlin et al. (1999)
FLT3 Complex formation Inhibits PLZF transcriptional repression and blocks PLZF-mediated growth
suppression of leukemia cells
Takahashi et al. (2004)
GATA1 Complex formation Plays an essential role in erythroid and megakaryocytic cell differentiation Labbaye et al. (2002)
GATA2 Complex formation PLZF modifies GATA2 transactivation capacity, which is implicated in the
survival and growth of multi-potential progenitors
Tsuzuki and Enver (2002)
HB-EGF Protein–protein interactions Functions as an intracellular signal and coordinates cell cycle progression
toward the S-phase
Nanba et al. (2003)
HDAC1 Complex formation Involved in the development of both lymphoid and myeloid leukemia David et al. (1998)
HDAC4 Complex formation Involved in leukemogenesis Chauchereau et al. (2004)
HDAC7 Complex formation Represses genes responsible for maintaining myeloid lineage potential Lemercier et al. (2002);
Dequiedt et al. (2003)
HoxD Chromatin remodeling Required for temporal and spatial co-linearity of normal limb development Barna et al. (2002)
mSin3 Complex formation Required for the inhibitory complex that mediates PLZF transcriptional
repression
David et al. (1998)
MTDH Protein–protein interactions Blocks PLZF transcriptional repression on c-Myc and increases the
potential of forming complexes with HDAC4 vs. HDAC1
Thirkettle et al. (2009)
N-CoR Complex formation Required for the recruitment of histone deacetylase to PLZF Huynh and Bardwell (1998)
PML/RARα Heterodimerization with
PLZF/RARα
Involved in the pathophysiology of acute promyelocytic leukemia (APL) Ruthardt et al. (1998)
pRB Protein–protein interactions Regulates many processes that are deregulated in cancer, including cell
cycle progression, apoptosis, and cellular differentiation
Benevolenskaya et al. (2005)
Sall4 Protein–protein interactions Implicated in maintaining PLZF localization inside the nuclear speckles Hobbs et al. (2012)
SMRT Complex formation Plays a role in the transcriptional silencing of PLZF-target genes Hong et al. (1997)
Sp1 Protein–protein interactions PLZF inhibits Sp1 transactivation of the epidermal growth factor receptor
promoter
Vallian et al. (1998)
VDR Protein–protein interactions Regulation of 1,25-dihydroxyvitamin D(3) response Ward et al. (2001)
VDUP1 Complex formation Modulates cell cycle through cyclin-A2 promoter activity and suppresses
IL-3 receptor expression
Han et al. (2003)
Proteins that interact with PLZF to regulate its transcriptional/biological activity in vivo and in vitro.
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PLZF binds Sall4 and maintains its localization inside nuclear
speckles of adult stem cells. This interaction prevents Sall4 from
binding to its target nucleotide sequences in heterochromatin,
therefore inhibiting its transcriptional activity, which is required
for differentiation (Hobbs et al., 2012).
CELL CYCLE AND APOPTOSIS
The first target gene identified for PLZF was cyclin-A2 (Yeyati et al.,
1999). Cyclins are proteins that regulate the function of many
small CDKs. These CDKs control the temporal coordination of
the cell cycle by modulating the functions of many enzymes and
transcriptional factors required for each mitotic step. cyclin-A2 in
particular is very important in the transition between cell cycle
phases as it regulates cdc2, which controls G1/S and G2/M check-
points (Russo et al., 1996). Early experiments on PLZF showed
that it repressed cell cycle progression in 32Dcl3 (G/GM) murine
myeloid cells causing them to accumulate in S-phase. A simi-
lar result was also observed in the NB4 leukemic cell line and
non-hematopoietic NIH3T3 cells. This was caused by the direct
interaction of PLZF with the cyclin-A2 promoter leading to the
suppression of its expression, which was needed for both G1/S
and G2/M transition. Rescuing cyclin-A2 expression in these cells
successfully rescued the growth suppression effect of PLZF (Yeyati
et al., 1999). Furthermore, Geminin, a known protein that initiates
DNA replication in the S-phase of the cell cycle, was found to bind
Hox regulatory DNA elements that are targeted by the BTB/POZ
domain of PLZF and affect the same target genes; the Hox family
(Luo et al., 2004).
Because PLZF expression has a pronounced impact on cell
cycle progression, different studies attempted to investigate its
direct role in causing apoptosis. Earlier reports showed that PLZF
overexpression caused interleukin-3 (IL-3)-dependent murine
hematopoietic precursor cells to accumulate in the G0/G1 phase
of the cell cycle. These cells also showed levels of apoptosis in cul-
ture as assessed by TUNEL and Annexin-V staining (Shaknovich
et al., 1998). In Jurkat cells, the induction of PLZF expression
caused similar outcomes with a significant decrease in the num-
ber of cells in S-phase and an accumulation of cells in G0 phase.
Additionally, more than 50% of cells stained positive for Annexin-
V after only 2 days in culture. This was also accompanied by a
down-regulation in the anti-apoptotic telomerase reverse tran-
scriptase (TERT ) gene and an up-regulation of tumor protein
p53-inducible nuclear protein 1 (TP53INP1), inhibitor of DNA
binding 1 (ID1), and inhibitor of DNA binding 3 (ID3); all of
which are apoptosis-inducing genes (Bernardo et al., 2007). In
a more direct observation, PLZF was shown to be responsible for
up-regulating caspase-3 enzymatic activity in HeLa cervical cancer
cells reflected by apoptosis-specific proteolytic cleavage of PARP
in whole-cell lysates (Rho et al., 2007).
GLUCOCORTICOID RESPONSE
Glucocorticoids (GC), such as cortisone and dexamethasone, are
a type of steroid hormones that are synthesized and secreted
by the adrenal cortex. They function through the GC recep-
tors, which are found in the vast majority of mammalian cells,
to regulate many essential biological functions, such as lipolysis,
glycolysis, and cardiovascular and immunological processes. In
a DNA microarray analysis using the T47D/A1-2 breast cancer
cell line, PLZF was found to be differentially induced by dex-
amethasone. This induction was suggested to be, in part, the
cause of breast cancer cell death after dexamethasone treatment
(Wan and Nordeen, 2002). Following a discovery of the PLZF
homolog in the bovine endometrium cDNA library, Fahnenstich
and her colleagues were able to show that PLZF is induced in pri-
mary human endometrial stromal cells and myometrial smooth
muscle cells after dexamethasone and hydrocortisone treatment
in vitro. They also demonstrated how human endometrial and
myometrial stromal cells expressed PLZF only during the mid-late
secretory phase of the menstrual cycle in vivo, where the levels
of GC and progesterone are relatively high (Fahnenstich et al.,
2003).
CHROMATIN REMODELING
The addition of an acetyl group to lysine residues in core his-
tones neutralizes the positive charge and dissociates neighboring
nucleosomes, allowing the DNA to be lightly enfolded and read-
ily accessible to regulatory factors such as transcription factors.
This powerful transcriptional regulatory mechanism is carried
out by two classes of enzymes: histone acetyltransferases (HAT)
and HDAC inhibitors (HDACi). The ability to regulate the func-
tion of these enzymes to manipulate the DNA transcriptional
signal in many disease backgrounds is crucial (Suliman et al.,
2012).
Since HDAC1 was shown to bind the fusion protein PLZF-
RARα, the attention on the PLZF repression effect was drawn
toward a possible HDAC–PLZF interaction, where the modulation
of HDACs may control the accessibility of transcription factors,
such as PLZF, to the promoter of its target genes (Grignani et al.,
1998). HDAC1, along with mSin3, binds to both the BTB/POZ as
well as the RD2 domains of PLZF. This interaction was necessary
for the transcriptional activity of PLZF to bind its cognate DNA
sequences in HeLa Chang liver cells. Luciferase reporter constructs
with PLZF-binding sites were used to assess the activity of PLZF in
the presence of trichostatin A (TSA); a potent pan HDACi. A sig-
nificant reduction in PLZF activity was observed when cells were
treated with TSA, emphasizing the impact of HDACs on PLZF
function (Hong et al., 1997).
Another study demonstrated that PLZF also interacts with
HDAC4 and the transcriptional repression effect of PLZF
was completely dependent on HDAC4 enzymatic activity
(Chauchereau et al., 2004). Subsequently, HDAC3, 5, 6, and 7
were also shown to be part of the mSin3/SMRT/N-CoR com-
plex, which is essential for PLZF activity (Huang et al., 2000; Kao
et al., 2000; Li et al., 2000). More importantly, the HDAC inter-
action is not a universal phenomenon for BTB/POZ-containing
proteins such as PLZF and BCL6 (Lemercier et al., 2002). In
contrast, both HIC-1 and γ-FBP-B are BTB/POZ transcrip-
tion factors, but they failed to interact with mSin3, N-CoR,
or SMRT. They also show resistance to TSA, as their tran-
scriptional repression is not affected by its treatment (Del-
tour et al., 1999). This shows that PLZF can be selectively
recruited by HDACs and that they depend on its transcrip-
tional repression capability in order to augment their biological
function.
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PLZF AND IMMUNITY
Interferons are a group of cytokines produced by the host cells after
infections or oncogenic transformations. They perform a funda-
mental function in instigating the innate immune response and
coordinating the profile of the acquired immune response against
a variety of immunological stimuli. IFNs function by activating
signal transducer and activator of transcription (STATs) factors
to induce the Janus kinase (Jak)–STAT signaling cascade. As dis-
cussed earlier, Xu et al. demonstrated that PLZF was required for
the anti-viral innate immune response in vivo. Using two renal
adenocarcinoma cell lines (RCC1 and ACHN), they showed that
PLZF up-regulated many immune response genes after IFN treat-
ment and that those genes contained putative PLZF-binding sites
in their promoter regions. Many ISGs failed to respond to high lev-
els of IFN in PLZF−/− mice after viral infection. The expression
levels of Oas1g, CXCL10, Rsad2 (Viperin), and Ifit2 were signifi-
cantly lower, showing the requirement of PLZF in the induction
of the anti-viral response (Xu et al., 2009).
Natural killer cells are a group of cytotoxic lymphocytes that
represent a powerful tool of the innate immune system. NK cells
can spontaneously lyse cells lacking self-antigen or the major his-
tocompatibility complex (MHC) class-I. PLZF expression affects
the effector function of NK cells. NK cells from PLZF−/− mice,
although constituting the same percentage of total lymphocytes as
compared to the wild-types, were functionally impaired. This was
reflected by their failure to spontaneously lyse Yac-1 cells (an NK
cell-specific target because of their missing MHC-1). This was also
true after poly I:C-mediated IFN activation. Moreover, Granzyme
B (GzmB) induction after IFN activation was also affected, with
a lower percentage of PLZF−/−splenic NK cells showing GzmB
positive staining. This impairment of IFN activation was con-
firmed to be the direct result of lost PLZF expression, which was
required by a specific subset of ISGs. In spite of the well-known
role of PLZF as a transcriptional repressor, a novel activator role
was described for the first time with regards to the IFN signal-
ing pathway, where phosphorylated PLZF binds to the promoter
regions of those ISGs and actively drives their transcription (Xu
et al., 2009).
Natural killer T-lymphocyte (NKT) cells are a heterogeneous
population of T cells that both express surface antigen mark-
ers designated for NK cells and recognize the Cd1d antigen that
presents many glycoprotein and lipid molecules. Invariant NKT
(iNKT) cells are a subgroup of NKT cells with distinctive prop-
erties. They express an invariant α chain of the T cell receptor
(TCR), a specific TCR-β chain that uses the variable region 8.2,
and they can respond to immunological stimuli by cytokine secre-
tion within minutes (Matsuda et al., 2008). PLZF expression was
found to be restricted to iNKT cells, with higher concentrations
at early stages of thymocyte development and very low expres-
sion levels as cells differentiate toward maturation. Loss of PLZF
expression in PLZF−/− mice did not affect the number of mature
iNKT cells, but did have a dramatic impact on their function.
Most iNKT cells expressed low levels of CD44, CD8, NK1.1, DX5,
NKG2D, CD244, CD24, and CD122. Conversely, they expressed
high levels of CD69 and failed to remain in the thymus after matu-
ration; instead accumulating in the liver, lymph nodes, and spleen.
Functionally, PLZF-deficient iNKT cells failed to secrete both IL-4
and IFNγ after immunological challenge, a hallmark of NKT cells
(Savage et al., 2008; Kreslavsky et al., 2009).
A similar scenario was observed in a subset of γδNKT cells
that share phenotypic and functional properties with NKT cells
and express PLZF endogenously. Vγ1+Vδ6.3/Vδ6.4+ cells are
the predominant subtype of γδNKT, which produce a repertoire
of cytokines after innate immune stimuli. Loss of PLZF expres-
sion in those cells completely shut down their capacity to secrete
these important cytokines. This functional deficiency was shown
to be the result of impaired intrinsic development of thymocytes
that leads to a reduction of activated CD44HiCD62Low cells in the
bone marrow. Furthermore, TCR-mediated signaling was shown
to be required for PLZF induction, which drives development of
γδNKT cells (Kreslavsky et al., 2009).
PLZF AND HEMATOPOIESIS
In 1995, a study described the relatively high expression of PLZF
inside the nuclear speckles of CD34+ progenitor cells purified
from human bone marrow. However, the expression levels of PLZF
decreased in these hematopoietic cells as they became more dif-
ferentiated. The study also noted the possibility of PLZF being
involved in a regulatory network of transcription factors to control
hematopoiesis (Reid et al., 1995).
One of the important activators of the PLZF promoter in the
early stages of hematopoietic development was found to be Evi-1.
Evi-1, which is usually up-regulated in many leukemias, was found
to bind, and subsequently activate, the promoter of PLZF in HEL,
KG1, and K562 cells in vivo. Although this interaction did not affect
the expression level of PLZF, a theory of short cis-acting sequences
working in a tissue-specific manner was proposed (Takahashi and
Licht, 2002).
In a more recent study, researchers used a xenograft model
of immunodeficient mice to study the role of PLZF in early
myeloid development. They performed bone marrow transplan-
tation of lineage− (lin−) umbilical human cord blood-derived
myeloid progenitor cells that had been transduced with PLZF
expression/knockdown vectors. They successfully demonstrated
that PLZF was able to regulate the differentiation capacity of these
myeloid progenitors. PLZF achieved this through the transcrip-
tional modulation of many key transcription factors involved in
myeloid differentiation, such as GFI-1, C/EBPα, LEF-1, DUSP6,
and ID2. This demonstrates how PLZF-controlled cellular prolif-
eration in early hematopoiesis is essential in establishing a balance
between the numbers of progenitor and fully differentiated cells
(Doulatov et al., 2009).
PLZF AND CANCER
The PLZF (ZBTB16) protein was discovered in a patient with APL
(which is characterized by abnormal accumulation of immature
granulocytes). The cause of the disease was found to be a translo-
cation t (11;17)(q23;q21) between RARα and PLZF. The fusion
proteins caused the progression of the leukemia by suppressing
many retinoic acid-regulated genes, thereby locking the differ-
entiation of granulocytes into the “promyelocyte” stage. Specif-
ically, the patient had a chromosomal rearrangement that led to
a reciprocal translocation where two fusion gene products were
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produced: PLZF-RARα and RARα-PLZF. PLZF is located in chro-
mosome 11q23 and RARα is located in chromosome 17q21. The
first form of the fusion protein “PLZF-RARα” is composed of full-
length PLZF until the second zinc finger of the protein, where a
breakpoint joins RARα domains B–F. The second fusion protein
RARα-PLZF binds the A domain of RARα with the remaining
seven zinc fingers (3–9) of PLZF (Chen et al., 1993).
Promyelocytic leukemia zinc finger-RARα works by forming
multi-protein complexes with other repressor molecules such as
SMRT, Sin3, HDACs, and N-CoR to block myeloid differentiation.
Chimeric mice expressing the fusion protein develop a retinoic
acid-resistant leukemia that requires the addition of an HDACi to
restore retinoic acid sensitivity (He et al., 1998). In vitro, dihydrox-
yvitamin D3 (D3) and transforming growth factor β1 (TGFβ-1)
drive the differentiation of the human monocytic U937 cell line.
Similarly, dimethyl sulfoxide (DMSO) can induce the differen-
tiation of the human promyelocytic leukemia HL-60 cell line.
PLZF-RARα expression blocked the D3-TGF-induced monocytic
and DMSO-induced granulocytic differentiation of both U937
and HL-60 cells, respectively (Ruthardt et al., 1997). These results
suggest that the dominant negative effect of PLZF-RARα may
involve the disruption of BTB/POZ-mediated obligate homod-
imerization, which can cause a loss of wild-type PLZF function.
Additionally, U937 cells expressing PLZF-RARα were able to pro-
liferate after prolonged retinoic acid treatment, which may be
explained by the ability of PLZF-RARα to induce Myc expression
and inhibit dual specificity phosphatase 6 (DUSP6) expression
(Rice et al., 2009).
Promyelocytic leukemia zinc finger-RARα was also shown to
interact with Bmi-1 and that interaction causes the fusion pro-
tein to lose its function. Both PLZF and PLZF-RARα were able
to bind Bmi-1 in vitro to form the PRC1 polycomb complex,
which can then be recruited to retinoic acid response elements
(RAREs), transforming the chromatin in those regions insen-
sitive to remodeling by HDACs. This could explain the non-
responsiveness phenotype to all-trans retinoic acid treatment in
PLZF-RARα-mediated APL patients (Spector and Lamond, 2011).
In a yeast two-hybrid screening, a new cervical cancer suppres-
sor 3 (CCS3) protein was found to interact with the BTB domain
of PLZF, reflecting the high expression of PLZF in normal cells
FIGURE 2 | Functions of PLZF. PLZF is involved in the transcriptional
regulation of many genes, which are responsible for modulating many
developmental biological processes including: cellular proliferation and cell
cycle control, myeloid and lymphoid cell development and differentiation,
programming of NKT and iNKT cells, spermatogenesis and spermatogonial
stem cell renewal, hematopoiesis, musculoskeletal-limb development,
megakaryocytic development, and cytokine production (©2012
Shutterstock.com).
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and the absence of expression in cancer cells. CCS3 expression
followed a similar pattern in human cervical cells. Restoring CCS3
expression in SiHa cervical cancer cells caused a dramatic change
in morphology, a reduction in the numbers of viable cells in cul-
ture, and increased apoptosis. CCS3 was shown to achieve this
by interacting with PLZF to repress PLZF-target genes, such as
CCNA2 (cyclin-A2; Rho et al., 2006).
The androgen-independent prostate cancer cell line DU145
lacks endogenous PLZF expression and that expression could
be restored by the ectopic expression of the androgen recep-
tor (AR). Overexpressing PLZF in these cells caused a marked
down-regulation of the pre-B-cell leukemia transcription factor
(PBX1) and led to decreased proliferation and survival in vitro.
However, this was not true in LNCaP cells, which are androgen-
dependent prostate cancer cells. This reflects the fact that PLZF-
mediated repression is androgen-dependent and indicates how
DU145 could escape androgen-based chemotherapy (Park et al.,
2003).
A similar study performed on primary malignant melanoma
tumors from 41 patients found that PLZF is expressed in the
majority of tumors in vivo, but this expression was lost in
melanoma cell lines cultured in vitro. The study also showed that
PBX1 expression increased as a result of low PLZF levels, which
may contribute to the tumorigenesis of melanoma. Additionally,
PLZF mRNA expression was used as a prognostic/survival index
for patients (Brunner et al., 2008).
The expression of PLZF has been found to be frequently lost in
the highly aggressive malignant mesothelioma cells as a result of
recurrent focal chromosomal deletions. Restoring the expression
of PLZF in these cells caused decreased viability in culture, reduced
colony formation in soft agar, increased apoptosis, and an up-
regulation of the cleaved Mcl-1 protein, which is a pro-apoptotic
marker. Despite earlier reports connecting PLZF expression with
Myc and cyclin-A2, no significant difference in the expression levels
of these genes was noted in the study (Cheung et al., 2010).
An analysis of the upstream translated region of human PLZF
revealed many putative binding sites for the CCAAT displacement
protein (CUX1). In vivo interaction between CUX1 and thePLZF
promoter was confirmed by electrophoretic mobility shift assay
(EMSA) and chip analysis. CUX1 was also able to bind to the pro-
moter region of PLZF in Caco-2/15 and HEK293 cells in vitro.
A reporter assay showed that CUX1 blocked the transcriptional
repression of PLZF in a dose-dependent manner. When assessing
the PLZF gene expression profile in different colon cancer cells,
an inverse relation was discovered between PLZF and CUX1 gene
expression (Fréchette et al., 2010).
DISCUSSION
Promyelocytic leukemia zinc finger is a transcription factor impli-
cated in major developmental and biological processes includ-
ing spermatogenesis, hind limb formation, hematopoiesis, and
immune regulation (Figure 2). PLZF achieves its transcriptional
regulatory activity by interacting with different partners to form
large multi-protein complexes that bind to the regulatory elements
in the promoter region of the target genes. Recently, PLZF has
become implicated in carcinogenesis as a tumor suppressor gene,
because of its ability to regulate the cell cycle and apoptosis in
many cell types.
Many biological functions of PLZF in differentiated cells
remain to be determined. The number of regulatory factors con-
trolled by PLZF or by its target genes is substantial. Although
expressed in many tissue types, its expression level is low compared
to the levels in stem cells or progenitor cells. However, this does not
mean that it has a limited function in differentiated cells, as can be
seen by the large cohort of biological functions listed in Table 2.
What is more intriguing is the fact that PLZF expression is lost in
many cancer cells (Figure 3). As discussed earlier, the loss of PLZF
expression has been correlated to many malignant phenotypes
in different cancer cell types, including increased proliferation,
enhanced invasiveness and motility, and resistance to apoptosis.
FIGURE 3 | PLZF expression levels in different cell types. PLZF is highly
expressed in stem cells and many early progenitor cells that ensure the
continuation of self-renewal and low differentiation potential. This expression
starts to decrease once the cell is committed to a specific lineage and PLZF is
minimally expressed once the cell is fully differentiated. If a differentiated cell
undergoes transformation, different mechanisms are likely involved to
completely shutdown PLZF expression in order for the transformed cell to
acquire new malignant phenotypes (©2012 Shutterstock.com).
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All of these features are required for cancer cell survival, there-
fore PLZF is considered to be a tumor suppressor gene. Thus the
requirement to turn off the expression of PLZF for tumorigenesis is
evident, but the exact mechanism has yet to be elucidated. Possible
mechanisms include epigenetic modifications or up-regulation of
other transcription factors in order to silence the unfavorable PLZF
expression, microRNAs to block mRNA translation, or signals to
reduce the stability of the PLZF protein.
Promyelocytic leukemia zinc finger can also regulate the expres-
sion of different microRNA molecules. This ability is important,
because it can aid in the understanding of how PLZF achieves the
transcriptional repression of many downstream targets. This also
adds an extra level of regulation to the already known promoter-
dependent transcriptional regulatory activities of PLZF. A single
microRNA molecule not only can target a single pre-mature
mRNA, but also can regulate a plethora of mRNA molecules, lead-
ing to an amplified transcriptional regulatory signal that could
affect the basic properties of the cell, including proliferation rate,
apoptosis resistance, migration, and invasiveness.
Understanding the biological activities of PLZF and its
DNA/protein/miR interaction network would augment our
understanding of its complex involvement in many pathways and
may delineate the potential of fine tuning its expression profile in
cancer cells. This would add to its value as a therapeutic target to
modulate malignant cellular characteristics in oncological disease
backgrounds.
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